Provided by Tiger Trade Technology Pte. Ltd.

Equillium Inc.

2.31
+0.04001.76%
Post-market: 2.350.0400+1.73%19:37 EDT
Volume:557.32K
Turnover:1.31M
Market Cap:146.05M
PE:-11.40
High:2.46
Open:2.30
Low:2.24
Close:2.27
52wk High:3.54
52wk Low:0.7562
Shares:63.23M
Float Shares:37.00M
Volume Ratio:1.39
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2026
EPS(LYR):-0.3909
ROE:-58.98%
ROA:-33.95%
PB:2.61
PE(LYR):-5.91

Loading ...

Company Profile

Company Name:
Equillium Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
15
Office Location:
2223 Avenida De La Playa,Suite 105,La Jolla,California,United States
Zip Code:
92037
Fax:
- -
Introduction:
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Directors

Name
Position
Bruce D. Steel
Chief Executive Officer and Director
Daniel M. Bradbury
Chairman of the Board and Director
Barbara Troupin
Director
Charles McDermott
Director
Mark Pruzanski
Director
Martha J. Demski
Director

Shareholders

Name
Position
Bruce D. Steel
Chief Executive Officer and Director
Christine Zedelmayer
Chief Operating Officer
Jason A. Keyes
Chief Financial Officer
Stephen Connelly
Chief Scientific Officer and President